Diversified Trust Co Sells 8,258 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Diversified Trust Co lessened its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 52.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 7,418 shares of the biotechnology company's stock after selling 8,258 shares during the quarter. Diversified Trust Co's holdings in Blueprint Medicines were worth $647,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Wellington Management Group LLP increased its position in Blueprint Medicines by 22.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company's stock worth $366,726,000 after buying an additional 729,055 shares during the period. State Street Corp increased its position in Blueprint Medicines by 16.2% during the third quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock worth $255,827,000 after acquiring an additional 385,818 shares during the period. Geode Capital Management LLC raised its stake in Blueprint Medicines by 1.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company's stock worth $136,942,000 after purchasing an additional 20,703 shares in the last quarter. American Century Companies Inc. boosted its holdings in Blueprint Medicines by 4.2% in the 2nd quarter. American Century Companies Inc. now owns 802,733 shares of the biotechnology company's stock valued at $86,519,000 after purchasing an additional 32,600 shares during the period. Finally, Millennium Management LLC grew its position in shares of Blueprint Medicines by 540.0% during the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company's stock worth $67,646,000 after purchasing an additional 529,566 shares in the last quarter.

Insider Buying and Selling

In related news, COO Christina Rossi sold 2,274 shares of the business's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total value of $216,257.40. Following the transaction, the chief operating officer now owns 71,657 shares in the company, valued at $6,814,580.70. The trade was a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey W. Albers sold 15,000 shares of the stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $89.77, for a total value of $1,346,550.00. Following the sale, the director now owns 157,557 shares of the company's stock, valued at approximately $14,143,891.89. The trade was a 8.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,720 shares of company stock valued at $2,177,846 in the last three months. Insiders own 4.21% of the company's stock.

Blueprint Medicines Trading Down 3.5 %

Shares of NASDAQ:BPMC traded down $3.20 during midday trading on Friday, hitting $87.43. 1,299,374 shares of the stock were exchanged, compared to its average volume of 736,812. The business's 50-day moving average price is $93.42 and its 200 day moving average price is $95.42. Blueprint Medicines Co. has a 12 month low of $72.24 and a 12 month high of $121.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The stock has a market capitalization of $5.55 billion, a price-to-earnings ratio of -41.44 and a beta of 0.61.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.08. The firm had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company's revenue for the quarter was up 126.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.20) EPS. Analysts predict that Blueprint Medicines Co. will post -3.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BPMC has been the subject of a number of analyst reports. Guggenheim reiterated a "buy" rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. JPMorgan Chase & Co. started coverage on Blueprint Medicines in a research report on Thursday, November 14th. They set an "overweight" rating and a $126.00 target price for the company. Wedbush reissued an "outperform" rating and set a $135.00 target price on shares of Blueprint Medicines in a report on Thursday, November 14th. UBS Group started coverage on Blueprint Medicines in a research note on Thursday, October 24th. They issued a "neutral" rating and a $88.00 price target for the company. Finally, JMP Securities reiterated a "market outperform" rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Monday, December 9th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines presently has an average rating of "Moderate Buy" and a consensus price target of $123.33.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.